From phage to product
NexaBiome Life Sciences is using its patented technology to develop a phage-based wound dressing that actively kills the key pathogen in diabetic foot infections (DFIs), the bacterium Staphylococcus aureus.

Bringing phage technology into wound care
Stabilised phages
The dressing contains stabilised bacteriophages, using our patented technology, helping them maintain their activity within a practical wound-care product.
Easy to use
The dressing is designed as a direct replacement for wound dressings already used to treat DFIs, so nurses and clinicians do not need to introduce additional steps or learn new techniques when treating patients.
Complementing standard of care
The wound dressing is designed for use alongside standard of care in patients who have not responded to front-line antibiotics.
A long-term solution to help tackle AMR
The phage cocktail (combination of phages) used in the wound dressing is selected to provide broad coverage of circulating pathogenic strains.
While phages have not yet been widely deployed in the clinic, it would be expected that bacteria, over time, may acquire resistance to individual phages within a cocktail. However, because phages are biological entities, there is a vast natural diversity of phages, including others that may be active against resistant bacteria.
In principle, it is therefore possible to replace any phage that has lost efficacy against the target with a new phage that has activity, offering an important advantage in addressing bacterial resistance over the longer term.

A sustainable antimicrobial business
Discover how we are developing products that overcome the commercial challenges facing new antimicrobials.